Cerity Partners LLC Invests $216,000 in CRISPR Therapeutics AG (NASDAQ:CRSP)

Cerity Partners LLC purchased a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 6,351 shares of the company's stock, valued at approximately $216,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Capital International Investors raised its stake in CRISPR Therapeutics by 10.3% in the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after purchasing an additional 816,789 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of CRISPR Therapeutics by 39.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock worth $150,029,000 after purchasing an additional 1,074,238 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of CRISPR Therapeutics by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 1,735,998 shares of the company's stock worth $68,329,000 after purchasing an additional 10,579 shares during the last quarter. Baker BROS. Advisors LP grew its holdings in shares of CRISPR Therapeutics by 55.1% in the fourth quarter. Baker BROS. Advisors LP now owns 1,308,011 shares of the company's stock worth $51,483,000 after purchasing an additional 464,936 shares during the last quarter. Finally, Bank of America Corp DE grew its holdings in shares of CRISPR Therapeutics by 12.0% in the fourth quarter. Bank of America Corp DE now owns 1,211,509 shares of the company's stock worth $47,685,000 after purchasing an additional 129,746 shares during the last quarter. Institutional investors own 69.20% of the company's stock.

Insider Buying and Selling

In other CRISPR Therapeutics news, Director Simeon George acquired 989,812 shares of the business's stock in a transaction dated Wednesday, July 16th. The stock was acquired at an average cost of $52.03 per share, for a total transaction of $51,499,918.36. Following the completion of the transaction, the director directly owned 1,730,179 shares of the company's stock, valued at $90,021,213.37. This represents a 133.69% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Naimish Patel sold 3,932 shares of the business's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total value of $141,316.08. Following the completion of the sale, the insider owned 6,068 shares of the company's stock, valued at $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.30% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. JMP Securities reaffirmed a "market outperform" rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, June 27th. The Goldman Sachs Group lowered their price target on CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating for the company in a research report on Thursday, May 8th. Barclays decreased their target price on CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating for the company in a research report on Friday, May 9th. Wall Street Zen raised shares of CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. Finally, Bank of America reduced their price target on shares of CRISPR Therapeutics from $79.00 to $78.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, CRISPR Therapeutics has an average rating of "Hold" and an average price target of $71.31.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock traded up $0.02 during trading hours on Friday, reaching $56.28. The stock had a trading volume of 1,477,990 shares, compared to its average volume of 2,568,560. CRISPR Therapeutics AG has a 52 week low of $30.04 and a 52 week high of $71.13. The company has a market cap of $4.86 billion, a price-to-earnings ratio of -12.47 and a beta of 1.82. The business's 50 day moving average price is $48.88 and its 200-day moving average price is $43.12.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. During the same period in the previous year, the business posted ($1.43) EPS. The firm's revenue was up 71.6% on a year-over-year basis. On average, sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.